NanoEntek

KOSDAQ-039860
KOSDAQ
Laboratory Analytical Instruments
Global Rank
#26571
Country Rank
#1233
Market Cap
84.44 M
Price
2.22
Change (%)
0.15%
Volume
7,730

NanoEntek's latest marketcap:

84.44 M

As of 11/13/2025, NanoEntek's market capitalization has reached $84.44 M. According to our data, NanoEntek is the 26571th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 84.44 M
Revenue (ttm) 23.18 M
Net Income (ttm) 1.2 M
Shares Out 38.09 M
EPS (ttm) 0.04
Forward PE 0.00
Ex-Dividend Date 12/29/2003
Earnings Date 11/14/2025
Market Cap Chart
Data Updated: 11/13/2025

NanoEntek's yearly market capitalization.

NanoEntek has seen its market value drop from ₩128.88 B to ₩124.18 B since 2014, representing a total decrease of 3.65% and an annual compound decline rate (CAGR) of 0.34%.
Date Market Cap(₩) Market Cap(USD) Change (%) Global Rank
11/13/2025 ₩124.18 B $84.44 M 15.53% 26571
12/30/2024 ₩104.52 B $70.03 M 4.81% 25656
12/28/2023 ₩99.72 B $76.79 M -37.48% 24857
12/29/2022 ₩159.51 B $126.01 M -20.11% 20804
12/30/2021 ₩199.66 B $167.72 M -13.56% 19896
12/30/2020 ₩230.98 B $212.51 M 54.9% 16436
12/30/2019 ₩149.11 B $128.24 M 33.92% 16860
12/28/2018 ₩111.35 B $99.1 M -23.52% 17303
12/28/2017 ₩145.59 B $135.39 M 18.67% 16457
12/29/2016 ₩122.68 B $100.6 M -30.95% 15923

Company Profile

About NanoEntek, Inc.

NanoEntek, Inc. is a leading company specializing in life-science lab equipment, in vitro diagnostic medical devices, and point-of-care diagnostic solutions. Headquartered in Seoul, South Korea, the company operates both domestically and internationally, focusing on innovative research, development, and production.

Key Products and Solutions

  • FREND System: A fluorescence immunoassay analyzer for accurate diagnostics.
  • BUDDI: A rapid diagnostic test analyzer for efficient testing.
  • Rapid Diagnostic Test Items: High-quality diagnostic solutions for various applications.
  • ADAM-rWBC: Residual white blood cell counters for precise cell analysis.
  • ADAMII/Fluorescence Stem Cell Counter: Advanced tools for stem cell research.
  • Fluorescence Cell Counters & Analyzers: Cutting-edge technology for cell analysis.
  • Brightfield Cell Counters: Reliable instruments for laboratory use.
  • Somatic Cell Counters: Essential for dairy and food safety testing.
  • Live-Cell Imaging System: Enables real-time monitoring of cell behavior.
  • Disposable Hemocytometers: Convenient and hygienic cell-counting solutions.

Company Background

Founded in 1987, NanoEntek has established itself as a trusted provider of diagnostic and laboratory equipment, serving healthcare and research communities worldwide.

Frequently Asked Questions

  • What is NanoEntek's (KOSDAQ-039860) current market cap?
    As of 11/13/2025, NanoEntek (including the parent company, if applicable) has an estimated market capitalization of $84.44 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • NanoEntek global market capitalization ranking is approximately 26571 as of 11/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.